Academic Journal
Q2Purinergic Signalling
About Purinergic Signalling
About Purinergic Signalling
Purinergic Signalling is a peer-reviewed scholarly journal published by Springer Science and Business Media B.V. (Netherlands). It focuses on Q2. Publication coverage spans 2004-2026.
Key indicators: ISSN 1573-9538, 1573-9546; H-index 73.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (73): Strong citation impact — 73 articles cited at least 73 times each, reflecting solid influence.
Publishing in Purinergic Signalling
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Purinergic Signalling?
1573-9538, 1573-9546.
Who publishes Purinergic Signalling?
Springer Science and Business Media B.V..
What are Purinergic Signalling's metrics?
H-index 73.
Where do I submit to Purinergic Signalling?
Via the official website.
Is Purinergic Signalling peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Adenosine and Purinergic Signaling; Neuroscience of respiration and sleep; Receptor Mechanisms and Signaling; Vagus Nerve Stimulation Research; Neurological Complications and Syndromes; Adolescent and Pediatric Healthcare.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,690.00 USD; 3,690.00 EUR; 2,990.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Targeting P2Y14R inhibits proliferation of cervical cancer cells and organoids and activates cAMP/PKA/CREB signaling pathway
Rui Li, Hai-Yun Xiong, Shi-Yu Chen, Yong Tang et al.
2026-10 · DOI: 10.1007/s11302-026-10192-0P2X7 receptor gene polymorphisms in atherosclerosis patients classified based on angiographic stenosis grading
Süleyman Ince, Ahu Soyocak, Funda Seher Özalp Ateş, Emrah Ermiş et al.
2026-10 · DOI: 10.1007/s11302-026-10190-2ATP is not always pro-inflammatory: rethinking purinergic signalling in cancer and autoimmunity
Mohamed S. Nafie, Mohamed K. Diab
2026-10 · DOI: 10.1007/s11302-026-10188-wPathSepsisNet: a pathway-aware temporal graph attention network integrating inflammatory crosstalk dynamics for early prediction of multi-organ dysfunction in sepsis
Hilal Ustundag, Songul Doganay
2026-10 · DOI: 10.1007/s11302-026-10185-zATP-sensing DNA origami nanodevices for targeted modulation of purinergic signaling in inflammatory tissue injury
Abdel-Aziz S. Shatat
2026-10 · DOI: 10.1007/s11302-026-10187-xThe role of natural polyphenols in purinergic signaling: from molecular mechanisms to physiological implications
Ujjawal Sharma, Simran Soni, Bunty Sharma, Deeksha Pal et al.
2026-10 · DOI: 10.1007/s11302-026-10183-1Correction to: Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data
Maria P. Abbracchio, Ernesto Damiani
2026-10 · DOI: 10.1007/s11302-026-10189-9Soluble P2X7 receptor (sP2X7R) as a marker of inflammation in pregnancy
Valentina Vultaggio-Poma, Selene Schio, Cristina Taliento, Rosa Galasso et al.
2026-10 · DOI: 10.1007/s11302-026-10186-yElectroacupuncture and P2X receptors: purinergic mechanisms in pain modulation
Rajaa Shaheen
2026-10 · DOI: 10.1007/s11302-026-10184-0Antagonism of P2X7 receptor function in synovial fibroblasts is a potential therapeutic manipulation in rheumatoid arthritis
Shi-Yan Zhang, Y. Tang, P. Illes
2026-10 · DOI: 10.1007/s11302-026-10181-3Impact of cryopreservation on immune cell subset frequencies in human peripheral blood mononuclear cells following assessment of monoclonal antibodies to CD39 and P2X7
Leon Koning, Ashleigh Splitt, Daniel Brungs, Martin G. Carolan et al.
2026-10 · DOI: 10.1007/s11302-026-10180-4Interaction between purinergic signalling and purinergic modulators with skin wound repair effectors: a systematic review of preclinical in vivo models
Silvânia Mól Pelinsari, Reggiani Vilela Goncalves, Patricia da Silva Mattosinhos, Mariáurea Matias Sarandy et al.
2026-10 · DOI: 10.1007/s11302-026-10178-yEffects on mouse melanoma and immune cells of P2X7 receptor positive allosterism by clemastine
Maria Luiza Thorstenberg, Simonetta Falzoni, Rocio Edith Garcia-Jacobo, Leticia Scussel Bergamin et al.
2026-10 · DOI: 10.1007/s11302-026-10179-xDifferential expression, activity, and fibroblast growth factor 2-mediated modulation of purine-metabolizing enzymes in cultured cortical astrocytes and microglia
Ryota Eguchi, Ken-ichi Otsuguro
2026-10 · DOI: 10.1007/s11302-026-10177-zThe P2X7 receptor: insights from the murine monoclonal antibody clone L4
Ronald Sluyter, Amal Elhage, Rachael Bartlett, Debbie Watson et al.
2026-08 · DOI: 10.1007/s11302-026-10176-0Is adenosine signalling entering the precision medicine era? From receptor pharmacology to patient stratification
Luca Antonioli, György Haskó
2026-08 · DOI: 10.1007/s11302-026-10175-1Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs)
Yenidis Teilor Scheibel, Symon Martins, André Paulo Turcatel, Francini Franscescon et al.
2026-08 · DOI: 10.1007/s11302-026-10174-2Responsiveness to adenosine diphosphate on carotid arterial and platelet functions in type 2 diabetic Otsuka Long-Evans Tokushima Fatty rats
Hideaki Tagashira, Kumiko Taguchi, Takayuki Nagano, Tsuneo Kobayashi et al.
2026-08 · DOI: 10.1007/s11302-026-10173-3The effect of P2RX7 functional SNPs on osteoblast cell phenotype, function and signalling- roles in bone homeostasis and osteogenesis
Luke Tattersall, Qiguang Wang, Anna Lisa Giuliani, Elena Adinolfi et al.
2026-08 · DOI: 10.1007/s11302-026-10171-5Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose–response meta-analysis of randomized controlled trials
Jeevarathinam Thirumalai, Indra Sivakumar, Saravanan Sekaran
2026-08 · DOI: 10.1007/s11302-026-10172-4Reviews
Community Reviews
Version History
October 9, 2026 at 9:56 pm
October 2, 2026